Psyence Biomedical is paying $500,000 in shares to acquire fellow psilocybin-based biotech Clairvoyant Therapeutics and its phase 2-stage alcohol use disorder (AUD) candidate. Privately-held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback